Skip to main content
. Author manuscript; available in PMC: 2015 May 12.
Published in final edited form as: Nat Commun. 2014 Nov 12;5:5165. doi: 10.1038/ncomms6165

Figure 5. FDI-6 retains activity in MDA-MB-231 and PEO-1 adenocarcinoma cell lines.

Figure 5

(a) 72 h treatment with FDI-6 shows dose dependent effect on cell growth in MDA-MB-231 and PEO-1 breast and ovarian cancer cell lines. (b) FDI-6 down-regulates CDC25B expression after 3 h treatment.